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The latest European Association of Urology (EAU) 
Guidelines on renal cell carcinoma (RCC) recommend 
offering extended lymph node dissection (LND) to patients 
with adverse clinical features and performing LND for 
staging purposes or local control in those with clinically 
enlarged lymph nodes (1). Of note, the strength of both 
recommendations is weak. Similarly, the expert opinion of 
the American Urological Association (AUA) renal cancer 
Guideline panel is that physicians should perform a lymph 
node dissection for staging purposes for patients with 
clinically concerning regional lymphadenopathy but not 
routinely in patients with localized RCC and clinically 
negative nodes (2).
These conflicting recommendations reflect the current 
controversial evidence on the indications, extent and 
prognostic impact of LND for RCC (3-6). Furthermore, 
they might partly explain the trend towards lower rates of 
LND over the last decades, with LND rates stabilizing after 
2010 in both Europe and US (7,8). 
Nowadays, key grey areas include: (I) the potential 
association of LND with survival in M0 and M1 patients; 
(II) the impact of LND template with survival outcomes; 
(III) the prognostic value of pN+ status; (IV) the association 
of LND with surgical morbidity; and (V) the (preoperative) 
prediction of patients most likely to harbor lymph node 
metastases. The most recent systematic review and meta-
analysis addressing these topics found low-to-moderate 
quality evidence showing an independent prognostic role 
but no therapeutic benefit of LND in most M0 or M1 
patients with RCC (3). Furthermore, available studies 
exploring the potential association of anatomic extent of 
LND with survival reached inconsistent results. Of note, 
a subset of high-risk nonmetastatic patients did experience 
long-term survival after surgical resection (3). In addition, 
in a recent study performance of LND at the time of 
nephrectomy improved patient’s risk stratification, resulting 
in a small, albeit nonnegligible, clinical benefit in selecting 
high-risk patients for further postoperative treatment (9). 
While acknowledging the current controversies on 
LND in RCC, decision-making is often challenging in 
daily surgical practice and often relies on the surgeon’s 
individual clinical expertise. Indeed, as urologic surgeons, 
we ultimately have to balance the potential benefits and 
harms of LND in the individual patient. In this regard, 
while LND is not associated with an increased risk of 
perioperative morbidity in experienced hands (3,5,10), 
preoperative identification of patients with nodal metastases 
is a key unmet need. 
This concept is  reinforced by the f inding that 
approximately 70% of patients showing suspected lymph 
nodes preoperatively do not harbor lymph node metastases 
at the final pathological analysis (11). 
168
Campi et al. Beyond the predictors of lymph node metastases in renal cell carcinoma
© Annals of Translational Medicine. All rights reserved.   Ann Transl Med 2019;7(8):168atm.amegroups.com
Page 2 of 4
Several nomograms, risk scores and multivariable 
regression models have been proposed to identify patients 
at higher risk of lymph node invasion (LNI) (3,6). Although 
these tools are still suboptimal to guide decision-making, 
interestingly the most common covariates associated with 
pN+ disease are tumour size, stage and grade along with 
radiographic lymphadenopathy (cN1) (3). 
In this scenario, Nini et al. should be commended for 
providing additional evidence to better contextualize the 
predictors of nodal metastases at surgery and/or nodal 
progression (NP) at follow-up in patients with RCC (12). 
The study, which included 2,485 patients with sporadic, 
unilateral RCC treated with partial or radical nephrectomy 
at a single tertiary referral Centre with a median follow-
up of 5 years, evaluated for the first time the potential 
association between tumour side and tumour location with 
the risk of LNI and/or NP. 
The decision to perform LND was driven by the 
presence of ≥T2 and/or cN1 disease, as well as palpable 
lymph nodes during surgery, according to surgeon’s 
preference. 
Regional LND included, on the right side, the renal 
hilar, pre- and retro-caval nodes, while on the left side, the 
renal hilar and para-aortic nodes. When an extended LND 
was sought, the inter-aorto-caval nodes were dissected 
beyond the regional template. 
Overall, 372 (15%) and 279 (11%) patients had cN1 
and cM1 disease, respectively. Notably, 43% of patients 
underwent LND with wither a regional (33%) or extended 
(10%) template. At final histopathological analysis, pN1 
disease was reported in 7% of patients. The median number 
of lymph nodes removed was 6 (IQR, 3–10) in the overall 
cohort, while 5 and 12 in patients undergoing regional and 
extended LND, respectively (P<0.01).
The study provided novel data on the impact of tumour 
side and location on LNI and/or NP rates. In this regard, 
in the cohort of patients undergoing LND (n=1,061, 43%), 
LNI rates were 18% for right-sided RCC while 12% for 
left-sided RCC (P=0.02). If stratified by tumour location, 
LNI rates were 11%, 10%, 0%, 12% and 26% for upper, 
middle, hilar, lower area and more than one kidney area, 
respectively (P<0.01). 
After stratification for both side and location, there was 
a statistically significant difference in LNI and/or NP rates 
among different tumour locations only when considering 
patients with tumours involving more than one area, which 
showed higher rates of nodal metastases as compared to all 
other single locations [Figures 1,2 of Ref. (12)]. 
In the subgroup analyses according to LND extent (no 
LND vs. regional vs. extended), patients with tumours 
involving multiple kidney areas not receiving LND had 
higher rates of NP as compared to patients with tumours 
involving single locations. On the contrary, there was 
no statistically significant difference in LNI and/or NP 
rates among different tumour locations when considering 
patients undergoing either regional or extended LND. 
Similarly, no significant differences in LNI and/or NP rates 
were found between right-sided versus left-sided tumours in 
the analyses stratified by LND extent. 
The sub-analyses excluding patients with pT1a RCC 
confirmed these findings. 
Importantly, at multivariable analyses, pathological 
tumour size, cM1, cN1, pT2 and pT3-T4 disease, as well 
as Fuhrman grade 3-4 were independent predictors of LNI 
and/or NP (all P≤0.01). Neither tumour side nor tumour 
location reached the independent predictor status. 
The study by Nini et al. (12) provides key findings in 
the context of the current literature. First, the study shed 
light on the potential impact of tumour side and location on 
the risk of LNI and NP in patients undergoing surgery for 
RCC. 
The rational for the study is grounded in the hypothesis 
that tumours with different sides and locations might have 
a different pattern of lymphatic drainage and consequently 
a different risk of LNI or NP. Intriguingly, despite patients 
with tumours involving multiple kidney locations appeared 
to have higher rates of nodal metastases in the analyses 
stratified by tumour side, tumor location was not associated 
with LNI or NP at final multivariable analysis (12). 
Moreover, as previously reported (1-3,6), the strongest 
predictors of nodal metastases at surgery were tumour size, 
stage and grade along with radiographic lymphadenopathy 
(cN1) and cM1 disease (3,11,13). 
Taken together, these findings suggest that decision-
making regarding indications and extent of LND for RCC 
should not rely on tumour side or location, but rather 
on selected “adverse clinical features” (1) which may aid 
surgeons in identifying patients most likely to harbor lymph 
node metastases at the time of nephrectomy. 
Second, the study highlights the importance of reporting, 
beyond LNI at surgery, NP as a key endpoint during the 
follow-up of patients undergoing nephrectomy with or 
without LND for RCC. Yet, uniform definitions of NP 
according to standardized imaging criteria are lacking. 
Third, the study highlights the unpredictable variability 
of lymphatic drainage from RCC (4,14). As previously 
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reported for upper tract urothelial carcinoma (15), 
the pattern of lymphatic spread from RCC is highly 
heterogeneous (16). We recently found that, in light of 
this variability, the extent of the most commonly dissected 
templates might be insufficient to catch the anatomic 
pattern of lymphatic drainage from RCC, especially for 
higher stage and right-sided tumors (4). In this view, the 
study by Nini et al. (12) further reinforce the concept that, 
while different sides have different drainage patterns and 
require different LND templates (4), prediction of nodal 
status and the extent of dissection cannot ultimately rely on 
tumour location. 
Despite the template for regional and extended LND 
reported by Nini and colleagues was codified and included 
the most critical anatomical sites (4,12), variability at a 
surgeon level might have impacted the number of nodes 
removed and the LNI and/or NP rates, potentially limiting 
the generalizability of study findings. Furthermore, as 
the probability of missing a positive node decreases with 
increasing number of LNs removed and the number of 
LNs needed for correct pN0 staging increases with higher 
pathological tumor stage and grade (17), the template 
reported by the Authors might have been still suboptimal to 
adequately assess LNI at surgery in some patients. 
W h i l e  w a i t i n g  f o r  m o r e  a c c u r a t e  m o d e l s  t o 
preoperatively predict the risk of LNI (6), we believe the 
decision to perform LND should be carefully tailored 
according to the individual clinical scenario, taking into 
account patient (life expectancy and comorbidity status), 
tumour [adverse clinical features (1,3)] as well as surgeon 
(experience and skills) factors. We acknowledge that only a 
subset of high-risk patients is likely to benefit from LND (3), 
and that LND is a technically demanding procedure that 
might theoretically increase the risk of perioperative 
morbidity (5). Yet, LND is the most accurate staging tool in 
RCC, with the potential to improve risk-stratification and 
provide long-term cancer control in selected patients. 
In light of the unpredictable nodal spread (4,5,16), we 
believe that, if performed, LND should always be extended 
and include the renal hilar, pre/para/retro-caval nodes (+/− 
inter-aortocaval nodes) for right-sided RCC while the renal 
hilar, pre/para-aortic and inter-aortocaval nodes for left-
sided RCC, both from the crus of the diaphragm to the 
aortic bifurcation (Figure 1). 
Figure 1 Intraoperative picture showing the anatomic template of extended lymph node dissection (LND) performed at our Institution for 
high-risk patients with right-sided renal cell carcinoma. (A) The LND template includes in all cases the renal hilar, pre/para/retro-caval 
nodes from the crus of the from the crus of the diaphragm to the aortic bifurcation; (B) in selected cases the dissection is further extended to 
inter-aortocaval nodes and common iliac vein nodes. IVC, inferior vena cava; CIA, common iliac artery.
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